Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Prime Medicine, Inc. | SVP, Finance and Chief Accounting Officer | Stock Option (right to buy) | 90.5K | Feb 21, 2024 | Direct | ||
AGIOS PHARMACEUTICALS, INC. | Principal Accounting Officer | Stock option (right to buy) | 3.56K | Jun 21, 2021 | Direct | ||
AGIOS PHARMACEUTICALS, INC. | Principal Accounting Officer | Common stock | 0 | $21.64 | Jun 21, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PRME | Prime Medicine, Inc. | Feb 21, 2024 | 1 | $0 | 4 | Feb 23, 2024 | SVP, Finance and Chief Accounting Officer |
PRME | Prime Medicine, Inc. | Apr 18, 2023 | 1 | $0 | 4 | Apr 20, 2023 | Officer |
PRME | Prime Medicine, Inc. | Mar 31, 2023 | 1 | $0 | 4 | Apr 4, 2023 | Interim Chief Financial Officer and Chief Accounting Officer |
PRME | Prime Medicine, Inc. | Oct 19, 2022 | 0 | $0 | 3 | Oct 19, 2022 | Interim Chief Financial Officer and Chief Accounting Officer. Exhibit 24 - Power of Attorney |
AGIO | AGIOS PHARMACEUTICALS, INC. | Jun 21, 2021 | 3 | -$17.9K | 4 | Jun 23, 2021 | Principal Accounting Officer |